Tricyclo Ring System Having The Hetero Ring As One Of The Cyclos Patents (Class 514/454)
  • Patent number: 10814248
    Abstract: A system, machines and methods for extracting select moieties, flavonoids, and essential oils from plant material without co-extracting chlorophyll, lipids and other undesirable constituents from plants. Super-cooled extraction techniques are taught. Likewise, according to embodiments methods provides 100% grain ethyl alcohol extract with a concentration of chlorophyll that is below 1%.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: October 27, 2020
    Assignee: Capna IP Capital, LLC
    Inventor: Yevgeniy Galyuk
  • Patent number: 10765643
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of seizures associated with Aicardi Syndrome. In one embodiment the seizures associated with Aicardi Syndrome are convulsive seizures; focal seizures with impairment or infantile spasm. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: September 8, 2020
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 10758481
    Abstract: Single-serve containers for use in brewing a cannabis-based beverage are described, as are methods for preparing a single-serve container configured for receipt in a single-serve brewing machine. The method includes: adding a processed cannabis product to the single-serve container; adding, to the single-serve container, at least one of an extraction or flavoring agent; and sealing the single-serve container.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: September 1, 2020
    Assignees: CannTrust Inc., Single Dose Solutions Inc.
    Inventors: Ronald Stuart Benson, Peter Hobbes, Claudio Gemmiti, Ilana Deborah Platt
  • Patent number: 10722490
    Abstract: This disclosures relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: July 28, 2020
    Assignee: Canopy Growth Corporation
    Inventor: Kurt Aron Levy
  • Patent number: 10716819
    Abstract: Food grade cannabis extracts and methods for their preparation that may reduce or eliminate the anxiety effect that cannabis may have on a user. Embodiments of the methods include providing raw botanical material; providing food grade glycerin; combining the botanical material with the glycerin; blending the botanical material and the glycerin to achieve a homogenous mixture; optionally pre-heating the mixture prior to being agitated; placing the mixture in a sealable container; providing an agitator; securing the container on or within the agitator, agitating the mixture and allowing the mixture to rest at various intervals; heating the mixture and allowing the mixture to cool at various intervals; straining the mixture; pressing the mixture; and then filtering the mixture to remove any remaining particulates to thereby produce a food grade cannabis extract suitable for at least medical use.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: July 21, 2020
    Assignee: Yabuwi, Inc.
    Inventor: Daniel Hartman Stoops
  • Patent number: 10709670
    Abstract: Provided herein are pharmaceutical compositions that comprise myrcene, optionally in admixture with cannabinoids and other terpenes, typically substantially free of THC and THCA, for targeting TRPV1 receptors. Also provided are methods of using the pharmaceutical compositions to desensitize TRPV1 receptors in order to treat pain, cardiovascular diseases such as cardiac hypertrophy, overactive bladder, and chronic cough.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: July 14, 2020
    Assignee: GBS GLOBAL BIOPHARMA, INC.
    Inventors: Andrea Small-Howard, Helen Turner
  • Patent number: 10709674
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: July 14, 2020
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 10675240
    Abstract: The present invention includes a transdermal composition which contains a pharmaceutically effective amount of a cannabinoid for delivery of the cannabinoid to the bloodstream of a user. The composition may comprise the following components: a surfactant-lecithin organogel; and a cannabinoid. The composition may also comprise an exogenous terpene. The cannabinoid is capable of diffusing from the composition into the bloodstream of the user, and may be used in methods for treating a patient suffering from a condition such as pain, nausea and emesis, convulsions, muscle spasm, inflammation, depression, and cachexia.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: June 9, 2020
    Assignee: MM Technology Holdings, LLC
    Inventors: Nicole Smith, Noel Erwin Palmer
  • Patent number: 10660872
    Abstract: Embodiments of the invention relate to methods for treatment of age-related cognitive decline in a patient comprising administering to the patient a low dose of tetrahydrocannabinol (THC), preferably in an amount of 10-400 micrograms (?g). THC may be administered in a variety of routes. Methods for delaying or slowing or reversing the progression of age-related cognitive decline using THC are also disclosed. The aforementioned methods may slow the progression of age-related cognitive decline. The cognitive decline may be in a patient suffering from Mild Cognitive Impairment (MCI) or a patient with no MCI, in which cognitive decline is prevented.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: May 26, 2020
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventor: Yosef Sarne
  • Patent number: 10653787
    Abstract: Embodiments of the invention relate to methods for the manufacture of a protein-bound cannabinoid, comprising: obtaining a cannabinoid or cannabis in a form selected from the group consisting of cannabis smoke, cannabis vapor, cannabinoid solution and cannabis extract, and combining the cannabis smoke, vapor, cannabinoid solution or cannabis extract with an aqueous solution or suspension comprising a plasma protein to form a protein-bound cannabinoid. Further embodiments relate to aqueous solutions comprising a plasma protein-bound cannabinoid and pharmaceutical compositions comprising cannabinoids bound to plasma protein.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: May 19, 2020
    Assignee: IZUN PHARMACEUTICALS CORP
    Inventors: William Z. Levine, Shmuel Cohen
  • Patent number: 10631682
    Abstract: In hot beverage cannabis related products, such as single use coffee systems as well as other coffee systems, the cannabinoids are not being infused into the beverages, such as coffee, during the brewing process. To solve this problem, a cannabinoid delivery system is provided. The cannabinoid delivery system includes various systems and methods of positioning cannabinoids and/or cannabis plant matter in locations and forms such that the cannabinoids are properly infused into the beverages.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: April 28, 2020
    Assignee: Drive Foods Corp
    Inventor: Rory Chesley Patrick Millikin
  • Patent number: 10597348
    Abstract: A cannabis infused oil is formed by collecting and drying raw cannabis material having a desired cannabinoid profile. Next, the raw dried cannabis material is blended with oil to obtain a cannabis infused oil mixture. Blending is performed without causing the cannabis material to become decarboxylated. Next, the cannabis material is filtered from the cannabis infused oil mixture thereby obtaining a cannabis infused oil. The cannabis infused oil has at least two cannabinoids present in the oil in accordance with the desired cannabinoid profile. Next, the cannabis infused oil is packaged for storage and shipment. The cannabis infused oil is formed without any alcohol, does not have any decarboxylated cannabinoids and is non-psychoactive. In one example, the cannabis infused oil has between 100 milligrams and 2,000 milligrams of cannabinoids per fluid ounce of cannabis infused oil. In another example, before blending with oil, the cannabis material is combined with alcohol.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: March 24, 2020
    Inventor: Jeff Nordahl
  • Patent number: 10576096
    Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective legality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: March 3, 2020
    Assignees: The Board of Regents of the University of Texas System, The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Lifen Cao, Jinming Gao, Xiumei Huang, Xiuquan Luo, Xinpeng Ma, Zachary R. Moore, Elizabeth I. Parkinson
  • Patent number: 10555927
    Abstract: Pharmaceutical preparations include at least one component that enhances sexual response and at least one other compound that enhances sexual sensitivity and pleasure. The component that enhances sexual response enhances blood flow to the genital region. Examples include compounds that dilate blood vessels, such as compounds that increase the amount of nitric oxide (NO) in the blood. The component that enhances sexual sensitivity and pleasure includes one or more cannabinoid compounds from the plant genus Cannabis, including extracted compounds, synthetic forms, and derivatives thereof. Examples include tetrahydrocannabinol (THC), the main psychoactive constituent of Cannabis, and cannabidiol (CBD), which is less or non-psychoactive and modulates THC activity. The ratio of THC/CBD can be selected depending on age, gender, physical health, and/or psychological condition of the user.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 11, 2020
    Assignee: ILYSM, LLC
    Inventor: Dennis M. Jenn
  • Patent number: 10555928
    Abstract: The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS, for use in pharmaceutical formulations. In particular it relates to BDS comprising cannabinoids obtained by extraction from cannabis.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: February 11, 2020
    Assignee: United Cannabis Corp.
    Inventors: Earnie Blackmon, Tony Verzura
  • Patent number: 10450289
    Abstract: Provided herein are compounds having the general formula compositions, and methods useful for treating cancer and neurodegeneration. The compounds comprise a mitochondria-targeting moiety linked to ?-lapachone or a ?-lapachone derivative.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: October 22, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Bennett Van Houten, Wei Qian, Chaemin Lim
  • Patent number: 10428040
    Abstract: Disclosed are processes for obtaining a cannabinoid extract and product from Cannabis plant material. This way cannabinoids can be isolated in a way that produces higher yields than prior art methods. The disclosed processes to almost pure cannabinoids. In addition the disclosed processes can be carried out easily on a large scale in an economically advantageous manner.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: October 1, 2019
    Inventor: Albert Jan Dijkstra
  • Patent number: 10350251
    Abstract: Disclosed here are compositions comprising powdered hemp seed, an emulsifier/dispersant such as lecithin (particularly soya lecithin), cannabis, and optionally other additives and excipients. Also described are methods of making the compositions. The compositions may be used, for instance, in the treatment of pain and for their anti-emetic (anti-nausea and anti-vomiting) properties, as well as for the treatment of anorexia and appetite enhancement. Kits containing the compositions, arranged for proper sequential dosing, and optionally including instructions for use are also disclosed.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: July 16, 2019
    Inventor: Keith Gerald Freeman
  • Patent number: 10307392
    Abstract: The disclosed invention generally relates to treatment and/or prevention of symptoms associated with cannabinoid responsive diseases and disorders in subjects in need thereof, as well as the method of administering therapeutically-effective amount of a pharmaceutical compound containing cannabinoids. The disclosed invention further relates to pharmaceutical compounds for treating and/or preventing symptoms associated with said diseases and disorders.
    Type: Grant
    Filed: October 21, 2017
    Date of Patent: June 4, 2019
    Inventor: Alexander Kariman
  • Patent number: 10278951
    Abstract: The present invention provides a method of orally treating opiate dependency in a patient in need thereof. The method includes: orally administering an aqueous composition including: tetrahydrocannabinol (THC); one or more aprotic solvents, for example, dimethyl sulfoxide; one or more protic solvents, for example ethanol; and water. Methods of orally reducing or preventing opiate withdrawal, orally reducing or preventing opiate withdrawal symptoms, orally treating post-surgical and chronic pain in a patient are also provided.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: May 7, 2019
    Inventor: Jon Newland
  • Patent number: 10258601
    Abstract: A composition for producing a pharmacological effect is provided, which includes a bio-active ingredient and a carrier liquid solution. The bio-active ingredient can be a cannabinoid, cannabinomimetic, or combination thereof capable of inducing a pharmacological effect. The cannabinomimetic can be or can include one or more isoprenoids. The carrier liquid composition can include ethanol, at least one lecithin, at least one fatty alcohol, a liposome, and an active compound that includes glycerin or glycerol. The bio-active ingredient is receivable by a cannabinoid receptor and/or an acetylcholine receptor, which causes the production of the pharmacological effect. The composition may also include flavoring agents and aromatherapy agents. The composition is deliverable to a user via vaporization. A method is provided for creating a pharmacological effect using the composition.
    Type: Grant
    Filed: December 23, 2017
    Date of Patent: April 16, 2019
    Inventor: Stephen C. Perry
  • Patent number: 10238706
    Abstract: An apparatus for the extraction of compounds from botanical material using a condensable gas solvent includes an extraction chamber wherein the feedstock is extracted while in a frozen state.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: March 26, 2019
    Assignee: MedReleaf Corp.
    Inventor: Istok Gorazd Nahtigal
  • Patent number: 10188628
    Abstract: A release lotion for delivering Cannabaceae derivatives, including THC made by combining an aqueous phase at least one humectant; wherein the humectant is present in the aqueous phase in the range of from about 1 to 99 wt. %; and an oil phase comprising Cannabaceae derivatives and at least one surfactant, wherein the surfactant is present in the oil phase in the range of from about 1 to 99 wt. %, and wherein the aqueous phase is added to the oil phase in a weight ratio of about 3:1 to 49:1 using low to medium shear mixing, and wherein the lotion is hydrophobic and has release properties.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: January 29, 2019
    Inventors: Alvin Kershman, Jeff Shear
  • Patent number: 10172870
    Abstract: The present invention provides new compositions and methods for treating and/or reversing organophosphate intoxication, manifested by both cholinergic and non-cholinergic crisis, in a mammal resulting from exposure to organophosphate compounds. The neurosteroidal compounds of this invention are those having the general structural formula of pregnane, androstane, 19-norandrostanes, and norpregnane with further moieties as defined herein. These compounds include, but are not limited to, ganaxolone, pregnanolone, and androstanediol and their analogs, salts and prodrugs. The present invention further relates to combining a therapeutically effective amount of a neurosteroidal compound with a standard organophosphate antidote (e.g. atropine, pralidoxime). The data suggests that neurosteroids are effective or more effective than benzodiazepines, whether given earlier or later than 40-min (up to several hours) after organophosphate compound exposure.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: January 8, 2019
    Assignee: The Texas A&M University System
    Inventor: Doodipala Samba Reddy
  • Patent number: 10058531
    Abstract: A dosage delivery film composition containing a botanical drug substance formable into a bioerodible dosage delivery film, the dosage delivery film composition including: (i) one or more of: a polymer, a plasticizer, a defoamer, or an antioxidant; (ii) a cannabinoid-cyclodextrin-terpene complex or a cannabinoid-terpene-surfactant micelle, and (iii) optionally, one or more of: a taste mask, a vasodilator, or a lipophilic vehicle to transport the botanical drug substance across the mucous membrane.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: August 28, 2018
    Assignee: Spartak LLC
    Inventor: Sergey Y. Chistov
  • Patent number: 10046018
    Abstract: Methods and formulations for increasing the water solubility and/or bioavailability of a phytocannabinoid compound is disclosed herein. In one example, a water-soluble phytocannabinoid formulation can comprise a phytocannabinoid; a non-ionic surfactant; and optionally, water. The weight ratio of phytocannabinoid content to non-ionic surfactant can be from 1:10,000 to 1:5.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: August 14, 2018
    Inventor: Eric Kuhrts
  • Patent number: 10028919
    Abstract: This disclosure teaches phospholipid nanoparticle compositions of cannabinoids formed from phospholipids and simpler lipids in an unfired sequential process that encapsulate a high concentration of cannabinoids, and create standardized precision-metered dosage forms of cannabinoids; yielding an increase cannabinoid transport across hydrophobic mucosa; increase the bioavailability of the cannabinoid 2-fold to 8-fold, decrease the dose of cannabinoids 2-fold to 8-fold less than an amount of cannabinoids needed to illicit the same therapeutic effect compared to raw and non-encapsulated cannabinoids; where the nanoparticle dynamic structure reduces the adverse effects of cannabinoids; and enable safe more efficacious cannabinoid therapy.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: July 24, 2018
    Assignee: NANOSPHERE HEALTH SCIENCES, LLC
    Inventor: Richard Clark Kaufman
  • Patent number: 10028904
    Abstract: The present invention includes a transdermal composition which contains a pharmaceutically effective amount of a cannabinoid for delivery of the cannabinoid to the bloodstream of a user. The composition may comprise the following components: a surfactant-lecithin organogel; and a cannabinoid. The composition may also comprise an exogenous terpene. The cannabinoid is capable of diffusing from the composition into the bloodstream of the user, and may be used in methods for treating a patient suffering from a condition such as pain, nausea and emesis, convulsions, muscle spasm, inflammation, depression, and cachexia.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: July 24, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Nicole Smith, Noel Erwin Palmer
  • Patent number: 9987319
    Abstract: The invention extends the utility of apparatus used to extract medicinal cannabis compounds into an eluate by separating a portion of medicinal cannabis compounds contained within a portion of eluate at a first extraction target level providing enough clean solvent to continue extraction operations. A high efficiency concentrator such as a rotary evaporator or a wiped film evaporator processes eluate from one or more tanks or extraction vessels creating clean solvent when extraction targets are met or when clean solvent is exhausted. This manages eluate concentration levels and limits the quantity of concentrated medicinal cannabis compounds on site at any moment in time. The invention enables a business model for keeping medicinal cannabis compounds within a legal system, and reduces pollution because law enforcement would no longer have to burn large quantities of cannabis plant matter.
    Type: Grant
    Filed: October 11, 2015
    Date of Patent: June 5, 2018
    Inventors: Andrew David Hospodor, Robert James Rapp
  • Patent number: 9956183
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: May 1, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Patent number: 9956186
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: May 1, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Patent number: 9956185
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: May 1, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Patent number: 9956184
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: May 1, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Patent number: 9949937
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: April 24, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Patent number: 9937146
    Abstract: A composition which includes Phenylalanine, Serine, Glutamine and GABA (?-aminobutyric acid). The composition contains the essential amino acids Phenylalanine; Glutamine; the non-essential amino acid Serine; and GABA (?-aminobutyric acid) in concentrations effective to influence or modulate the neurotransmitter pentapeptide enkephalin. The composition may further comprise tetrahydrocannabinol (THC).
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: April 10, 2018
    Assignee: BIOADATP, LLC
    Inventor: Kevin Meehan
  • Patent number: 9901607
    Abstract: A cannabis composition includes a cannabis material and an additive solution. Cannabis material includes flowers, sugar leaves, and fan leaves from a cannabis plant, and can be configured to be finely cut or coarsely cut. An additive solution includes honey and a cannabis extract. Further disclosed is a method of manufacture of a cannabis composition, including a method for allowing a cannabis composition to ferment and a method of heating a cannabis composition.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: February 27, 2018
    Inventor: Mark J. Silen
  • Patent number: 9844534
    Abstract: The invention is directed to compounds that are specific inhibitors of PKC delta, and methods and compositions for the treatment and prevention of cancers and other disorders. Compositions comprising compounds of the invention are used to treat cancers such as, for example, carcinoid and neuroendocrine tumors, malignant melanomas, pancreatic, gastrointestinal and lung cancers. Neuroendocrine tumor cell lines of pulmonary and gastrointestinal origin are surprisingly sensitive to PKC delta inhibition by the compounds of the invention. The invention is further directed to methods, compositions and kits containing compounds of the formulas (Ia), (IIa), (IIIa), (IVa), and (V) as disclosed and described in FIGS. 11 and 12.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: December 19, 2017
    Assignee: Faller & Williams Technology, LLC
    Inventors: Douglas V. Faller, Robert M. Williams
  • Patent number: 9844530
    Abstract: This invention generally relates to methods of treatment of glaucoma and symptomatic relief of conjunctival inflammation. An ophthalmic solution comprising cannabinoids for the treatment of glaucoma and an ophthalmic solution comprising cannabinoids for these purposes are disclosed. Cannabinoids are selected to achieve the specific purpose of the respective ophthalmic solution.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: December 19, 2017
    Assignee: Axim Biotechnologies, Inc.
    Inventors: George Anastassov, Lekhram Changoer
  • Patent number: 9784740
    Abstract: Disclosed are positive allosteric modulators (PAMs) and silent allosteric modulators (SAMs) for mu (?)-opioid receptors that may be useful for the treatment of pain, either alone or in combination with orthosteric opioid receptor agonists. Methods for treating pain and modulating mu (?)-opioid receptors are also disclosed.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: October 10, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Neil Burford, Andrew Alt
  • Patent number: 9675579
    Abstract: The present invention relates to the use of tetrahydrocannabivarin (THCV) in the treatment of nausea and vomiting. Preferably the THCV is isolated and/or purified from cannabis plant extracts. Preferably the nausea and/or vomiting is caused by the effects of a medication such as a chemotherapeutic agent.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: June 13, 2017
    Assignee: GW Pharma Limited
    Inventors: Erin Rock, Linda Parker, Marnie Duncan, Colin Stott
  • Patent number: 9669002
    Abstract: The invention relates to the use of one or more cannabinolds in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type II diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: June 6, 2017
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Roger Pertwee
  • Patent number: 9655910
    Abstract: This invention relates to compositions containing combinations of a balanced PC composition and one or more cannabinoids, a natural or synthetic derivative thereof, or a salt thereof, and kits containing such combinations and methods of using such combinations to treat subjects suffering from addiction to substances and related diseases or disorders. This invention also relates to the synergistic effect of such combination therapies in humans.
    Type: Grant
    Filed: March 1, 2015
    Date of Patent: May 23, 2017
    Assignee: BODYBIO INC.
    Inventors: Edward Kane, Patricia Kane, Brett T Hauser
  • Patent number: 9603887
    Abstract: The present invention relates to a pharmaceutical composition comprising non-decarboxylated ?9 Tetrahydrocannabinol (THC), Cannabidiol (CBD), and at least one small molecule selected from Citric Acid, Ascorbic Acid, Citrus Essential Oil(s), Lecithin, one or more sugar(s), Resvertrol, and combinations thereof, wherein the composition exhibits an increased but negated psychoactivity with concurrent enhancement in therapeutic potency of THC and/or CBD. The present invention is further directed to methods of treating one or more disease(s) or disorder(s) modulated by the activation of the Cannabinoid CB1 and/or CB2 receptors, by administering a therapeutically effective amount of the composition of the present invention to a subject in need thereof.
    Type: Grant
    Filed: January 1, 2014
    Date of Patent: March 28, 2017
    Assignee: Brooks Kelly Research, LLC
    Inventor: Brooks J. Kelly
  • Patent number: 9572793
    Abstract: The invention is directed to compounds that are specific inhibitors of PKC delta, and methods and compositions for the treatment and prevention of cancers and other disorders. Compositions comprising compounds of the invention are used to treat cancers such as, for example, carcinoid and neuroendocrine tumors, malignant melanomas, pancreatic, gastrointestinal and lung cancers. Neuroendocrine tumor cell lines of pulmonary and gastrointestinal origin are surprisingly sensitive to PKC delta inhibition by the compounds of the invention. The invention is further directed to methods, compositions and kits containing compounds of the formulas (Ia), (IIa), (IIIa), (IVa), and (V) as disclosed and described in FIGS. 11 and 12.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: February 21, 2017
    Assignee: Faller & Williams Technology, LLC
    Inventors: Douglas V. Faller, Robert M. Williams
  • Patent number: 9549906
    Abstract: The disclosure provides methods of treatment of ocular inflammation and/or neuropathic pain in a subject in need thereof, comprising administering to the subject in need thereof a CB2 target agent, a cannabimimetic agent or a combination thereof. The agent is optionally a cannabinoid, such as a non-psychotropic cannabinoid or a synthetic cannabinoid. In certain embodiments, the non-psychotropic phytocannabinoid is ?-caryophyllene or cannabidiol [CBD] and the synthetic cannabinoid is HU-433, HU-308, or a modified CBD such as CBD-DMH. In methods of the disclosure, CBD-DMH is optionally administered in combination with a further CB2 target agent or cannabimimetic agent. The disclosure also provides ocular pharmaceutical compositions containing the CB2 target agents and/or cannabimimetic agents described herein.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: January 24, 2017
    Inventors: Mary Lynch, Melanie Kelly
  • Patent number: 9522123
    Abstract: This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: December 20, 2016
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Benjamin Whalley, Gary Stephens, Claire Williams, Geoffrey Guy, Stephen Wright, Tetsuro Kikuchi
  • Patent number: 9469878
    Abstract: Disclosed herein are methods for determining whether an individual with cancer is suitable for a treatment with an NQO1 bioactivatable drug, predicting responsiveness of an individual with cancer to a treatment with an NQO1 bioactivatable drug, and treating an individual with cancer with an NQO1 bioactivatable drug composition.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: October 18, 2016
    Assignee: The Board of Regents of the University of Texas System
    Inventors: David Boothman, Jinming Gao, Erik Bey, Ying Dong
  • Patent number: 9422260
    Abstract: A new process for the manufacture of iodinated xanthenes in high purity includes a cyclization step followed by an iodination step. No extraction, chromatographic or solvent concentration steps are required, and the intermediate as well as final compounds are isolated via filtration or similar means. The process requires a single organic solvent, and the steps are completed at temperatures below 100° C. The exclusion of chloride ions, of chloride free-radicals, hypochlorite ions, or hypochlorous acid as reagents or from reagents that may generate these species in situ in the presence of oxidants, prevents undesirable impurity formation. Several new compounds have been conceived and isolated using these methods. These new compounds are also formed into new medicaments.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: August 23, 2016
    Assignee: PROVECTUS PHARMATECH, INC.
    Inventors: Jamie Singer, Eric A. Wachter, Timothy Scott, Marlon Lutz, Kevin Babiak
  • Patent number: 9421187
    Abstract: The present invention relates to one or more of the phytocannabinoids tetrahydrocannabivarin (THCV); cannabigerol (CBG); cannabichromene (CBC); and cannabidivarin (CBDV) for use in the treatment of intestinal inflammatory diseases. Preferably the intestinal inflammatory disease is either ulcerative colitis or Crohn's disease.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: August 23, 2016
    Assignee: GW Pharma Limited
    Inventors: Angelo Antonio Izzo, Francesca Borrelli, Stephen Wright
  • Patent number: 9408828
    Abstract: The present invention provides a compound, namely (+)-3?-Angeloyloxy-4?-keto-3?,4?-dihydroseselin (Pd-Ib) derived from Bupleurum malconense as the potential anti-inflammation drug. The present invention also relates to methods of preparing the compounds and using the same for treating inflammation.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: August 9, 2016
    Inventors: Zhaoxiang Bian, Huaixue Mu, Chengyuan Lin, Quanbin Han, Aiping Lu, Linfang Huang, Shilin Chen, Dajian Yang, Hongxi Xu, Sun Chi Albert Chan